Mytos is a biotechnology company offering contract development and manufacturing organisation (CDMO) services focused on regenerative medicine. It leverages its proprietary iDEM™ automation technology to replace manual cell culture workflows. The company aims to reduce cost per dose, accelerate scale-up, and allow clinical-stage and advanced developers to access GMP-level manufacturing without the usual infrastructure burdens. Mytos operates its first facility within the UK’s CGT Catapult Stevenage site, with plans for a series of global sites.

Key Products and Services:

• iDEM™ Automation Technology: Automates unit operations in cell culture (coating, seeding, feeding, imaging, passaging, harvesting) while using the same 2D T-flask format as manual methods. Enables process transfer without changing biology.
• Automated CDMO Services Complete service offering: from Process & Analytical Development to Regulatory Support. Designed to lower cost, increase consistency, and scale manufacturing for cell therapies.
• Manufacturing Facilities:  First site housed at CGT Catapult’s Stevenage Manufacturing Innovation Centre; additional cleanroom space available; future global sites planned.
• Cost & Efficiency Advantages:  Compared to manual CDMOs, Mytos claims up to 50% lower batch costs, up to 10× reduction in labour and cleanroom footprint per batch. No suite fees or device purchase required for clients.
• Therapeutic Coverage / Applications:  Works across multiple indications, including brain, eye, bone, and other regenerative medicine areas. Partnerships with cell-therapy developers for neuronal precursor cells, cell therapies for deafness, bone fracture, corneal blindness etc.

Mytos positions itself at the intersection of automation, cell therapy and CDMO service provision, aiming to overcome scaling and cost barriers in regenerative medicine. By embedding its iDEM technology in manufacturing sites, and offering turnkey services, the company seeks to enable clinical and commercial scale production without the delays or high capital investment typical of traditional facilities. Its strategy of launching multiple global sites could provide meaningful support to developers looking to bring advanced cell-based therapies to patients more rapidly.